Istituto Oncologico Veneto IRCCS   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Padova Italy (2005)

Organization Overview

First Clinical Trial
2012
NCT01941992
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Istituto Oncologico Veneto IRCCS

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Small Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Colonic Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Hypersensitivity (Phase 2)

Mucositis (Phase 2)

Neoplasms (Phase 1)

Sarcoma (Phase 3)

Small Cell Lung Carcinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomatitis (Phase 2)

Triple Negative Breast Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 26